The effects of traditional Chinese medicine and dietary compounds on digestive cancer immunotherapy and gut microbiota modulation: A review.
The effects of traditional Chinese medicine and dietary compounds on digestive cancer immunotherapy and gut microbiota modulation: A review.
复制标题
传统中药和膳食化合物对消化道癌症免疫治疗和肠道微生物群调节的影响：综述。
DOI：
10.3389/fimmu.2023.1087755
复制
发表时间：
2023
影响因子：
7.3
通讯作者：
Hu Y
中科院分区：
文献类型：
--
作者：
Feng X;Li Z;Guo W;Hu Y
消化道相关癌症占全球十大高危癌症中的四种。近年来，利用先天免疫系统攻击肿瘤的癌症免疫疗法导致了癌症治疗的范式转变。肠道微生物群修饰已广泛用于调节癌症免疫治疗。膳食化合物和中药 (TCM) 可以改变肠道微生物群及其对有毒代谢物产生的影响，例如伊普林多对脂多糖 (LPS) 的影响，以及参与与免疫反应密切相关的各种代谢途径。因此，探索胃肠癌新的免疫疗法，阐明不同膳食化合物/中药对肠道菌群的免疫调节作用，是一种有效的策略。在这篇综述中，我们总结了膳食化合物/中药对肠道微生物群及其代谢物的影响，以及消化道癌症免疫治疗与肠道微生物群之间关系的最新进展。我们希望该综述能够起到参考作用，为肠道菌群调节消化道肿瘤的临床免疫治疗提供理论基础。
Digestive tract-related cancers account for four of the top ten high-risk cancers worldwide. In recent years, cancer immunotherapy, which exploits the innate immune system to attack tumors, has led to a paradigm shifts in cancer treatment. Gut microbiota modification has been widely used to regulate cancer immunotherapy. Dietary compounds and traditional Chinese medicine (TCM) can alter the gut microbiota and its influence on toxic metabolite production, such as the effect of iprindole on lipopolysaccharide (LPS), and involvement in various metabolic pathways that are closely associated with immune reactions. Therefore, it is an effective strategy to explore new immunotherapies for gastrointestinal cancer to clarify the immunoregulatory effects of different dietary compounds/TCMs on intestinal microbiota. In this review, we have summarized recent progress regarding the effects of dietary compounds/TCMs on gut microbiota and their metabolites, as well as the relationship between digestive cancer immunotherapy and gut microbiota. We hope that this review will act as reference, providing a theoretical basis for the clinical immunotherapy of digestive cancer via gut microbiota modulation.
登录
查看更多内容
DOI：
10.1002/hep.30319
发表时间：
2019-08
期刊：
Hepatology (Baltimore, Md.)
影响因子：
--
作者：
Banales JM;Iñarrairaegui M;Arbelaiz A;Milkiewicz P;Muntané J;Muñoz-Bellvis L;La Casta A;Gonzalez LM;Arretxe E;Alonso C;Martínez-Arranz I;Lapitz A;Santos-Laso A;Avila MA;Martínez-Chantar ML;Bujanda L;Marin JJG;Sangro B;Macias RIR
通讯作者：
Macias RIR
影响因子：
4.6
作者：
Bian S;Wan H;Liao X;Wang W
通讯作者：
Wang W
影响因子：
24.5
作者：
Chen, Feng;Dai, Xudong;Zhou, Chang-Chun;Li, Ke-Xin;Zhang, Yu-Juan;Lou, Xiao-Ying;Zhu, Yuan-Min;Sun, Yan-Lai;Peng, Bao-Xiang;Cui, Wei
通讯作者：
Cui, Wei
杜瓦卢马布（Durvalumab）和非小细胞肺癌中的tremelimumab的安全性和抗肿瘤活性：多中心1B研究。
DOI：
10.1016/s1470-2045(15)00544-6
发表时间：
2016-03
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Antonia S;Goldberg SB;Balmanoukian A;Chaft JE;Sanborn RE;Gupta A;Narwal R;Steele K;Gu Y;Karakunnel JJ;Rizvi NA
通讯作者：
Rizvi NA
影响因子：
5.9
作者：
Beam A;Clinger E;Hao L
通讯作者：
Hao L